FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2906360069> ?p ?o ?g. }

• W2906360069 endingPage "263.e7" @default.
• W2906360069 startingPage "263.e1" @default.
• W2906360069 abstract "Background Characterization of pharmacokinetics is lacking for vaginal progesterone in pregnancy. Dosing of vaginal progesterone for preterm birth prevention has been empirical. Owing to pregnancy-related changes in vaginal and uterine blood flow, hepatic metabolism, renal clearance, and endogenously elevated serum progesterone, studies outside of pregnancy may not be applicable. The lack of the pharmacokinetics profile of vaginally administered progesterone in pregnancy limits the ability to define the exposure–response relationship needed to optimize dosing, which has implications for its use in research and clinical care regarding management of short cervix, prevention of recurrent preterm birth, and prevention of recurrent miscarriage. Objective This was a study to establish the feasibility of using serum progesterone to establish basic pharmacokinetic parameters of vaginal progesterone in pregnancy for preterm birth prevention. Study Design This is a prospective study of 6 low-risk singletons at 18 0/7 to 23 6/7 weeks’ gestation with body mass index 20–40. Exclusion criteria were current vaginitis, abnormal Pap smear, prescription medication use, cervical length ≤25 mm, prior preterm birth, and contraindication to progesterone. Participants received a single dose of 200 mg micronized vaginal progesterone and serum progesterone levels were evaluated every 2 hours from 0 to 12 hours and then 24 hours post dose. Primary outcome was concentration/time profile of serum progesterone. Results Median (range) maternal age was 27 (21.5–33.3) years, median body mass index was 26.5 (23.3–29.0) kg/m2, and median gestational age was 22.9 (21.0–23.4) weeks. Median baseline serum progesterone was 47 (40–52) ng/mL, median peak concentration was 54 (48–68) ng/mL, and median time to peak was 12 (4–15) hours. There was a trend in rising serum progesterone over baseline with a median change in peak concentration of 11 ng/mL and interquartile range of 2–22. Median percent change from baseline was an increase by 24% (interquartile range, 4%–53%). However, there was no clear elimination phase and the median area under the curve was 112 ng*h/mL with an interquartile range of -43 to 239. Conclusion Unlike in nonpregnant individuals, administration of vaginal progesterone in pregnant individuals only minimally impacts systemic exposure. There is a limited trend of rising serum progesterone over baseline levels, with significant inter-individual variability. Serum progesterone is unlikely to be a good candidate for establishing pharmacokinetics or dosing of vaginal progesterone in pregnancy for preterm birth prevention. Characterization of pharmacokinetics is lacking for vaginal progesterone in pregnancy. Dosing of vaginal progesterone for preterm birth prevention has been empirical. Owing to pregnancy-related changes in vaginal and uterine blood flow, hepatic metabolism, renal clearance, and endogenously elevated serum progesterone, studies outside of pregnancy may not be applicable. The lack of the pharmacokinetics profile of vaginally administered progesterone in pregnancy limits the ability to define the exposure–response relationship needed to optimize dosing, which has implications for its use in research and clinical care regarding management of short cervix, prevention of recurrent preterm birth, and prevention of recurrent miscarriage. This was a study to establish the feasibility of using serum progesterone to establish basic pharmacokinetic parameters of vaginal progesterone in pregnancy for preterm birth prevention. This is a prospective study of 6 low-risk singletons at 18 0/7 to 23 6/7 weeks’ gestation with body mass index 20–40. Exclusion criteria were current vaginitis, abnormal Pap smear, prescription medication use, cervical length ≤25 mm, prior preterm birth, and contraindication to progesterone. Participants received a single dose of 200 mg micronized vaginal progesterone and serum progesterone levels were evaluated every 2 hours from 0 to 12 hours and then 24 hours post dose. Primary outcome was concentration/time profile of serum progesterone. Median (range) maternal age was 27 (21.5–33.3) years, median body mass index was 26.5 (23.3–29.0) kg/m2, and median gestational age was 22.9 (21.0–23.4) weeks. Median baseline serum progesterone was 47 (40–52) ng/mL, median peak concentration was 54 (48–68) ng/mL, and median time to peak was 12 (4–15) hours. There was a trend in rising serum progesterone over baseline with a median change in peak concentration of 11 ng/mL and interquartile range of 2–22. Median percent change from baseline was an increase by 24% (interquartile range, 4%–53%). However, there was no clear elimination phase and the median area under the curve was 112 ng*h/mL with an interquartile range of -43 to 239. Unlike in nonpregnant individuals, administration of vaginal progesterone in pregnant individuals only minimally impacts systemic exposure. There is a limited trend of rising serum progesterone over baseline levels, with significant inter-individual variability. Serum progesterone is unlikely to be a good candidate for establishing pharmacokinetics or dosing of vaginal progesterone in pregnancy for preterm birth prevention." @default.
• W2906360069 created "2019-01-01" @default.
• W2906360069 creator A5022533472 @default.
• W2906360069 creator A5041269947 @default.
• W2906360069 creator A5041549211 @default.
• W2906360069 creator A5058640471 @default.
• W2906360069 date "2019-09-01" @default.
• W2906360069 modified "2023-10-16" @default.
• W2906360069 title "Pharmacokinetics of vaginal progesterone in pregnancy" @default.
• W2906360069 cites W1679568553 @default.
• W2906360069 cites W1972536653 @default.
• W2906360069 cites W1991349082 @default.
• W2906360069 cites W2016068805 @default.
• W2906360069 cites W2024576502 @default.
• W2906360069 cites W2081278205 @default.
• W2906360069 cites W2085754255 @default.
• W2906360069 cites W2089780784 @default.
• W2906360069 cites W2110330014 @default.
• W2906360069 cites W2111925739 @default.
• W2906360069 cites W2141878965 @default.
• W2906360069 cites W2150216889 @default.
• W2906360069 cites W2167191293 @default.
• W2906360069 cites W2169827333 @default.
• W2906360069 cites W2515565831 @default.
• W2906360069 cites W2572899228 @default.
• W2906360069 cites W262836470 @default.
• W2906360069 cites W2755562766 @default.
• W2906360069 cites W2759659974 @default.
• W2906360069 cites W2768850026 @default.
• W2906360069 cites W2782005131 @default.
• W2906360069 cites W2793171097 @default.
• W2906360069 cites W2892071664 @default.
• W2906360069 cites W2897567760 @default.
• W2906360069 cites W2934301299 @default.
• W2906360069 cites W4242030375 @default.
• W2906360069 cites W84583857 @default.
• W2906360069 doi "https://doi.org/10.1016/j.ajog.2019.06.019" @default.
• W2906360069 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6732017" @default.
• W2906360069 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31211965" @default.
• W2906360069 hasPublicationYear "2019" @default.
• W2906360069 type Work @default.
• W2906360069 sameAs 2906360069 @default.
• W2906360069 citedByCount "12" @default.
• W2906360069 countsByYear W29063600692019 @default.
• W2906360069 countsByYear W29063600692020 @default.
• W2906360069 countsByYear W29063600692021 @default.
• W2906360069 countsByYear W29063600692022 @default.
• W2906360069 countsByYear W29063600692023 @default.
• W2906360069 crossrefType "journal-article" @default.
• W2906360069 hasAuthorship W2906360069A5022533472 @default.
• W2906360069 hasAuthorship W2906360069A5041269947 @default.
• W2906360069 hasAuthorship W2906360069A5041549211 @default.
• W2906360069 hasAuthorship W2906360069A5058640471 @default.
• W2906360069 hasBestOaLocation W29063600692 @default.
• W2906360069 hasConcept C112705442 @default.
• W2906360069 hasConcept C126322002 @default.
• W2906360069 hasConcept C131872663 @default.
• W2906360069 hasConcept C2778376644 @default.
• W2906360069 hasConcept C2779234561 @default.
• W2906360069 hasConcept C2779245376 @default.
• W2906360069 hasConcept C29456083 @default.
• W2906360069 hasConcept C46973012 @default.
• W2906360069 hasConcept C54355233 @default.
• W2906360069 hasConcept C71924100 @default.
• W2906360069 hasConcept C86803240 @default.
• W2906360069 hasConceptScore W2906360069C112705442 @default.
• W2906360069 hasConceptScore W2906360069C126322002 @default.
• W2906360069 hasConceptScore W2906360069C131872663 @default.
• W2906360069 hasConceptScore W2906360069C2778376644 @default.
• W2906360069 hasConceptScore W2906360069C2779234561 @default.
• W2906360069 hasConceptScore W2906360069C2779245376 @default.
• W2906360069 hasConceptScore W2906360069C29456083 @default.
• W2906360069 hasConceptScore W2906360069C46973012 @default.
• W2906360069 hasConceptScore W2906360069C54355233 @default.
• W2906360069 hasConceptScore W2906360069C71924100 @default.
• W2906360069 hasConceptScore W2906360069C86803240 @default.
• W2906360069 hasIssue "3" @default.
• W2906360069 hasLocation W29063600691 @default.
• W2906360069 hasLocation W29063600692 @default.
• W2906360069 hasLocation W29063600693 @default.
• W2906360069 hasOpenAccess W2906360069 @default.
• W2906360069 hasPrimaryLocation W29063600691 @default.
• W2906360069 hasRelatedWork W1963932479 @default.
• W2906360069 hasRelatedWork W2016096381 @default.
• W2906360069 hasRelatedWork W2039758761 @default.
• W2906360069 hasRelatedWork W2041600248 @default.
• W2906360069 hasRelatedWork W2048833152 @default.
• W2906360069 hasRelatedWork W2057156863 @default.
• W2906360069 hasRelatedWork W2121096509 @default.
• W2906360069 hasRelatedWork W2412598178 @default.
• W2906360069 hasRelatedWork W4286784551 @default.
• W2906360069 hasRelatedWork W1755616925 @default.
• W2906360069 hasVolume "221" @default.
• W2906360069 isParatext "false" @default.
• W2906360069 isRetracted "false" @default.
• W2906360069 magId "2906360069" @default.
• W2906360069 workType "article" @default.